ES2187788T3 - Compuestos esteroides oxigenados en las posiciones 6 y 7 y sus usos. - Google Patents

Compuestos esteroides oxigenados en las posiciones 6 y 7 y sus usos.

Info

Publication number
ES2187788T3
ES2187788T3 ES97929071T ES97929071T ES2187788T3 ES 2187788 T3 ES2187788 T3 ES 2187788T3 ES 97929071 T ES97929071 T ES 97929071T ES 97929071 T ES97929071 T ES 97929071T ES 2187788 T3 ES2187788 T3 ES 2187788T3
Authority
ES
Spain
Prior art keywords
oxygen substitution
positions
steroid compounds
disclosed
oxygen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97929071T
Other languages
English (en)
Inventor
David L Burgoyne
Yaping Shen
John M Langlands
Christine Rogers
Joseph H-L Chau
Edward Piers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Alberta
University of British Columbia
Inflazyme Pharmaceuticals Ltd
Original Assignee
University of Alberta
University of British Columbia
Inflazyme Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Alberta, University of British Columbia, Inflazyme Pharmaceuticals Ltd filed Critical University of Alberta
Application granted granted Critical
Publication of ES2187788T3 publication Critical patent/ES2187788T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0007—Androstane derivatives not substituted in position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
    • C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/005—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 16 (17)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/008—Ketals at position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0016—Oximes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/0026—Oxygen-containing hetero ring cyclic ketals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

LA INVENCION SE REFIERE A COMPUESTOS ESTEROIDES QUE PRESENTAN DIVERSAS SUSTITUCIONES POR OXIGENO SOBRE EL NUCLEO ESTEROIDE. UNA FUNCIONALIDAD ESPECIFICA PRESENTE EN MUCHOS COMPUESTOS ESTEROIDES ES LA SUSTITUCION POR OXIGENO EN POSICIONES 6 Y 7. POR TANTO, CIERTOS ESTEROIDES PRESENTAN UNA SUSTITUCION POR OXIGENO EN POSICIONES C6 Y C7, Y ALGUNOS PRESENTAN UNA ESTEREOQUIMICA ESPECIFICA, COMO UNA SUSTITUCION POR OXIGENO 6 AL Y 7 BE . SE DESCRIBEN ASIMISMO ESTEROIDES CON UNA FUNCIONALIDAD EPOXI EN POSICION 3,4. ADEMAS, SE DESCRIBEN ESTEROIDES CON UNA FUNCIONALIDAD PIRANO C17 Y DE -LACTONA, CON UNA SUSTITUCION POR OXIGENO EN C6 Y C7, O EN C15, DEL NUCLEO ESTEROIDE.
ES97929071T 1996-07-11 1997-07-11 Compuestos esteroides oxigenados en las posiciones 6 y 7 y sus usos. Expired - Lifetime ES2187788T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2345096P 1996-07-11 1996-07-11
US67964296A 1996-07-12 1996-07-12

Publications (1)

Publication Number Publication Date
ES2187788T3 true ES2187788T3 (es) 2003-06-16

Family

ID=26697171

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97929071T Expired - Lifetime ES2187788T3 (es) 1996-07-11 1997-07-11 Compuestos esteroides oxigenados en las posiciones 6 y 7 y sus usos.

Country Status (13)

Country Link
US (5) US6046185A (es)
EP (1) EP0917534B1 (es)
JP (1) JP2001503732A (es)
KR (1) KR100533436B1 (es)
AT (1) ATE229031T1 (es)
AU (1) AU722815B2 (es)
BR (1) BR9710353A (es)
CA (1) CA2259981C (es)
DE (1) DE69717633T2 (es)
ES (1) ES2187788T3 (es)
NZ (1) NZ333731A (es)
RU (1) RU2196143C2 (es)
WO (1) WO1998002450A2 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2245224A1 (en) * 1998-08-14 2000-02-14 Jiang-Hong Giong Chemokine receptor antagonists and chemotherapeutics
AU762472B2 (en) 1998-03-13 2003-06-26 University Of British Columbia, The Therapeutic chemokine receptor antagonists
CA2305787A1 (en) * 2000-05-09 2001-11-09 The University Of British Columbia Cxcr4 antagonist treatment of hematopoietic cells
US20080015174A1 (en) * 1998-11-24 2008-01-17 Reading Christopher L Metabolic Disease Treatments
US6667299B1 (en) * 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
US20030083231A1 (en) * 1998-11-24 2003-05-01 Ahlem Clarence N. Blood cell deficiency treatment method
CA2335109A1 (en) * 2000-04-12 2001-10-12 Chemokine Therapeutics Corporation Cxcr4 agonist treatment of hematopoietic cells
US7368425B2 (en) * 2006-03-24 2008-05-06 Chemokine Therapeutics Corp. Cyclic peptides for modulating growth of neo-vessels and their use in therapeutic angiogenesis
US7378098B2 (en) * 2000-04-12 2008-05-27 The University Of British Columbia CXC chemokine receptor 4 agonist peptides
US20050059584A1 (en) * 2002-08-16 2005-03-17 Ahmed Merzouk Novel chemokine mimetics synthesis and their use
MXPA02010645A (es) * 2000-04-28 2004-04-20 Inflazyme Pharm Ltd Esteroides de 3-nitrogeno-5, 7-dioxigeno y usos relacionados con los mismos.
JP2004531560A (ja) * 2001-05-21 2004-10-14 アルコン，インコーポレイテッド ドライアイ障害を処置する方法
PL367286A1 (en) 2001-05-21 2005-02-21 Alcon, Inc. Use of nfkb inhibitors to treat dry eye disorders
US6696580B2 (en) * 2001-05-22 2004-02-24 Inflazyme Pharmaceuticals Ltd. Process for the production of 6,7-diols of steroidal compounds
WO2003082893A2 (en) * 2002-03-27 2003-10-09 Phytopharm Plc Theraputic methods and uses of sapogenins and their derivatives
GB0217930D0 (en) * 2002-08-02 2002-09-11 Glycologic Ltd A chemical carrier
WO2004089304A2 (en) * 2003-04-01 2004-10-21 Hollis-Eden Pharmaceuticals, Inc. Antiandrogens with marginal agonist activity and methods of use
ES2359916T3 (es) 2003-04-15 2011-05-30 Aquinox Pharmaceuticals Inc. Derivados de indeno como agentes farmacéuticos.
CA2582231A1 (en) * 2004-09-29 2006-10-19 Hollis-Eden Pharmaceuticals, Inc. Steroid analogs and uses
MX2008010921A (es) * 2006-03-02 2008-09-03 Mallinckrodt Inc Procesos para preparar productos de morfinan-6-ona con bajos niveles de compuestos de cetona alfa, beta-insaturados.
CN101884638B (zh) * 2010-07-09 2011-11-09 中山大学 5α-雄甾(烷)-3β,5,6β-三醇在制备神经元保护药物中的应用
CN102617685B (zh) * 2012-03-08 2014-01-22 广州市赛普特医药科技有限公司 雄甾-3β,5α,6β-三醇的晶型化合物及其制备方法
JP6407950B2 (ja) 2013-03-14 2018-10-17 アクイノックス ファーマシューティカルズ （カナダ） インコーポレイテッド Ｓｈｉｐ１モジュレーターおよびそれに関連する組成物および方法
KR20220110337A (ko) 2013-03-14 2022-08-05 에퀴녹스 파머수티칼스 (캐나다) 인코포레이티드 Ship1 조절제 및 그와 관련된 방법
CN104072564B (zh) * 2013-03-28 2016-08-17 广州市赛普特医药科技股份有限公司 2β,3α,5α-三羟基-雄甾-6-酮及其制备方法与用途
CA2986790A1 (en) 2015-06-26 2016-12-29 Aquinox Pharmaceuticals (Canada) Inc. Crystalline solid forms of the acetate salt of (1s,3s,4r)-4-((3as,4r,5s,7as)-4-(aminomethyl)-7a-methyl-1-methyleneoctahydro-1h-inden-5-yl)-3-(hydroxymethyl)-4-methylcyclohexanol
WO2017127753A1 (en) 2016-01-20 2017-07-27 Aquinox Pharmaceuticals (Canada) Inc. Synthesis of a substituted indene derivative
EP3423465A1 (en) 2016-03-02 2019-01-09 Patheon Austria GmbH & Co KG Process and intermediates for the production of 17(20)-ene b-seco steroids
JP6892278B2 (ja) * 2017-02-10 2021-06-23 あすか製薬株式会社 １５−オキソステロイド化合物及びその製造方法
AU2019247453A1 (en) 2018-04-06 2020-10-22 Taro Pharmaceuticals Inc. Hexadecahydro-1H-cyclopenta[a]phenanthrene derivatives useful in treating pain and inflammation
AU2019247513A1 (en) 2018-04-06 2020-10-22 Taro Pharmaceuticals Inc. Indene derivatives useful in treating pain and inflammation
JP2021526545A (ja) 2018-04-06 2021-10-07 アキノックス ファーマシューティカルス（カナダ）インク． 疼痛及び炎症を治療するのに有用なインデン誘導体
WO2023213151A1 (zh) * 2022-05-06 2023-11-09 奥锐特药业股份有限公司 一种醋酸阿比特龙及其中间体的制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3026320A (en) * 1958-11-28 1962-03-20 Syntex Sa Derivatives of cortisone and hydrocortisone
JPS4122178Y1 (es) * 1964-12-16 1966-11-04
US3681410A (en) * 1970-08-07 1972-08-01 Syntex Corp Process for preparing 17{60 -hydroxy-20-keto and 17{60 ,21-dihydroxy-20-keto pregnanes and derivatives and intermediates thereof
BE792321A (fr) * 1971-12-08 1973-06-05 Roussel Uclaf Nouveaux 18,19-dinor 13,beta-alcoyl pregna 4,9,11-trienes et procede depreparation
ES427522A1 (es) 1973-06-25 1976-12-16 Scherico Ltd Un procedimiento para la preparacion de un 3-ceto-6-arido-4.6-bis-deshidroesteroide.
CH606090A5 (es) * 1974-07-30 1978-10-13 Ciba Geigy Ag
GB1490852A (en) * 1974-09-12 1977-11-02 Leo Pharm Prod Ltd Fusidic acid derivatives
US5002961A (en) * 1987-10-19 1991-03-26 Merrell Dow Pharmaceuticals Method for reducing injury with imidazol-2-thionecarboxamides
US5017573A (en) * 1988-07-29 1991-05-21 Dainippon Pharmaceutical Co., Ltd. Indazole-3-carboxylic acid derivatives
DK603988D0 (da) * 1988-10-28 1988-10-28 Klaus Bendtzen Farmaceutisk praeparat
DE4005516A1 (de) * 1989-02-24 1990-08-30 Henkel Corp Verfahren zur umwandlung (alpha)-acetyl-substituierter lactone in (alpha)-alkyliden-substituierte lactone
US5079239A (en) * 1990-02-16 1992-01-07 Harbor Branch Oceanographic Institution, Inc. Sterol disulfates and methods of use
US5219879A (en) * 1990-03-05 1993-06-15 Du Pont Merck Pharmaceutical Company Heterocyclic steroid compounds
GB9212511D0 (en) * 1992-06-12 1992-07-22 Cortecs Ltd Pharmaceutical compositions
FR2696934B1 (fr) * 1992-10-20 1995-06-02 Conservatoire Nal Arts Metiers Dérivés de stéroïdes naturels 3B hydroxyles ayant des propriétés de déclenchement et de stimulation de l'immunité, composition les contenant et procédé pour les obtenir.
CA2086221C (en) * 1992-12-23 2003-07-15 Raymond J. Andersen Contignasterol, and related 3-alpha hydroxy-6-alpha hydroxy-7-beta hydroxy-15-keto-14-beta steroids useful as anti-inflammatory and anti-thrombosis agent
US5506221A (en) * 1992-12-24 1996-04-09 University Of British Columbia Contignasterol, and related 3-alpha hydroxy-6-alpha hydroxy-7-beta hydroxy-15-keto-14-beta steroids useful as anti-inflammatory and anti-thrombosis agents
US5763435A (en) * 1995-11-21 1998-06-09 Children's Hospital Medical Center Sulfate conjugates of ursodeoxycholic acid, and their beneficial use in inflammatory disorders

Also Published As

Publication number Publication date
US7067682B2 (en) 2006-06-27
AU722815B2 (en) 2000-08-10
ATE229031T1 (de) 2002-12-15
RU2196143C2 (ru) 2003-01-10
US20040162425A1 (en) 2004-08-19
US6706701B1 (en) 2004-03-16
US20060211857A1 (en) 2006-09-21
DE69717633D1 (de) 2003-01-16
US20040157814A1 (en) 2004-08-12
EP0917534A2 (en) 1999-05-26
KR20000023661A (ko) 2000-04-25
EP0917534B1 (en) 2002-12-04
NZ333731A (en) 2000-09-29
CA2259981C (en) 2008-06-10
KR100533436B1 (ko) 2006-01-09
US6046185A (en) 2000-04-04
JP2001503732A (ja) 2001-03-21
AU3332397A (en) 1998-02-09
WO1998002450A2 (en) 1998-01-22
BR9710353A (pt) 2000-01-11
DE69717633T2 (de) 2003-10-02
CA2259981A1 (en) 1998-01-22
US6949533B2 (en) 2005-09-27

Similar Documents

Publication Publication Date Title
ES2187788T3 (es) Compuestos esteroides oxigenados en las posiciones 6 y 7 y sus usos.
ES2155874T3 (es) Composiciones cosmeticas que contienen acido betulinico.
FI964748A (fi) Huoneenlämpötilan sterilointiaine
ES2179273T3 (es) N-bencil-2-fenilindolas como agentes estrogenicos.
BG99261A (en) Steroid glycosides for the treatment of hyperchlesterolemia
DE68901043D1 (de) Waessriges pharmazeutisches praeparat.
ATE241337T1 (de) Hautpflegemittel für gealterte haut
MX9301643A (es) Composiciones de fragancia, no terapeuticas que contienen feromonas de humano.
TR199701544T1 (xx) Yeni dolastatin t�revleri,bunlar�n haz�rlanmas� ve kullan�lmas�.
BR9713338A (pt) Benzonaftiridinas como terapêuticos brÈnquicos.
ES2105551T3 (es) Utilizacion de derivados de la resorcina substituidos en posicion(es) 4,4 y 5 o 4 y 6 en unas composiciones cosmeticas o dermofarmaceuticas con accion despigmentante.
ES2104090T3 (es) Nuevas 3',5'-di-t-butil-4'-hidroxi-flavonas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen.
ATE160573T1 (de) 1,3.5 (10) - estratriene derivate mit oraler wirkung
KR950700988A (ko) 미생물, 이들의 제조방법 및 이들의 사용(Micro-organisms, preparation method therefor and uses thereof)
HUP9800464A2 (hu) Illatosított fehérítőkészítmények
JPS53141611A (en) Keying system of electronic musical instrument
MX166043B (es) Particulas expansibles y expandidas de polimero alquenil aromatico
EP1304333A3 (en) 6,7-Oxygenated steroids and uses related thereto
ES2112511T3 (es) Derivado de saintopina.
BR0012008A (pt) Composição cosmética; e uso de uma composição
DK1036167T3 (da) Kernemålretning ved hjælp af Streptococcus protein H
MY106167A (en) 6-substituted purinyl piperazine derivatives.
PH15494A (en) D-homosteroids and pharmaceutical preparations thereof
ES2081629T3 (es) Composiciones odoriferas.
KR970034534A (ko) 실내 공기순환방법